

O I P  
JUN 02 2004  
PATENT & TRADEMARK OFFICE

JUN 14 2004  
TECH CENTER 2900  
USPTO

SHEET 1 OF 1

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 4220-78-PUS	SERIAL NO. 10/049,427
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANT THOR	
		FILING DATE May 6, 2002	GROUP ART 1617

#### U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROP.

#### FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION
							YES NO

#### OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)

GM	A1.	Hamilton et al., "Determination of dapoxetine, an investigational agent with the potential for treating depression, and its mono- and di-desmethyl metabolites in human plasma using column-switching high-performance liquid chromatography," <i>Journal of Chromatography</i> 1993, 612:253-261
GM	A2.	Waldinger et al., "Antidepressants and ejaculation: a double-blind, randomized, fixed-dose study with mirtazapine and paroxetine," <i>J. Clin Psychopharmacology</i> 2003, 23(5):467-470, Abstract only, from PubMed - PMID:14520123
GM	A3.	Kennedy et al., "Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and venlafaxine," <i>J. Clin Psychiatry</i> 2000, 61(4):276-281, Abstract only, from PubMed - PMID:10830148

EXAMINER	Gregory T. Notley II	DATE CONSIDERED	03/03/05
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			